HK Stock Market Move | Asymchem Laboratories (06821) rose by over 3%, with the net profit attributable to the mother increasing by 12.66% year-on-year in the first three quarters. Emerging businesses are expected to become the core growth engine.

Asymchem Laboratories (06821) rose by more than 3%, reaching 3.12% at the time of writing, to report 85.8 Hong Kong dollars, with a trading volume of 1368.32 million Hong Kong dollars. On the news front, recently, Asymchem Laboratories announced that in the first three quarters of 2025, the group achieved operating income of 4.63 billion yuan, an increase of 11.82% year-on-year; net profit attributable to shareholders of the listed company was 800 million yuan, an increase of 12.66% year-on-year; and basic earnings per share were 2.18 yuan. The announcement stated that based on the distribution of orders waiting to be delivered in the second half of the year, the delivery scale in the fourth quarter will significantly exceed that of the third quarter, and it is expected that the full year operating income will achieve a 13%-15% growth. Guosen pointed out that as the cornerstone business of Asymchem Laboratories, the revenue of the small molecule CDMO business in the first three quarters of 2025 was basically flat year-on-year, with a gross profit margin of 47.0% (-1.9pp). The growth of emerging businesses was strong, with the revenue of emerging businesses in the first three quarters of 2025 increasing by 71.9% year-on-year, and the gross profit margin was 30.6% (+10.6pp), with the revenue of the chemical large molecule business growing by over 150% year-on-year. In terms of new signed orders, the company continued to increase its market development efforts in emerging businesses such as peptides, oligonucleotides, and ADCs, with new signed orders maintaining double-digit growth. With the company's capacity expansion, emerging businesses are expected to become the core growth engine.